Na+–K+–2Cl− Cotransport Inhibitor Attenuates Cerebral Edema Following Experimental Stroke via the Perivascular Pool of Aquaporin-4
- 11 May 2010
- journal article
- Published by Springer Science and Business Media LLC in Neurocritical Care
- Vol. 13 (1), 123-131
- https://doi.org/10.1007/s12028-010-9376-8
Abstract
The Na+–K+–2Cl− cotransporter localized in the brain vascular endothelium has been shown to be important in the evolution of cerebral edema following experimental stroke. Previous in vivo studies have demonstrated that bumetanide, a selective Na+–K+–2Cl− cotransport inhibitor, attenuates ischemia-evoked cerebral edema. Recently, bumetanide has been shown to also inhibit water permeability via aquaporin-4 (AQP4) expressed in Xenopus laevis oocytes. We tested the hypothesis that the perivascular pool of AQP4 plays a significant role in the anti-edema effect of bumetanide by utilizing wild-type (WT) mice as well as mice with targeted disruption of α-syntrophin (α-Syn−/−) that lack the perivascular pool of AQP4. Isoflurane-anesthetized adult male WT C57Bl6 and α-Syn−/− mice were subjected to 90 min middle cerebral artery occlusion (MCAO) followed by 24 or 48 h of reperfusion. Adequacy of MCAO and reperfusion was monitored with laser-Doppler flowmetry over the ipsilateral parietal cortex. Infarct volume (tetrazolium staining), cerebral edema (wet-to-dry ratios), and AQP4 protein expression (immunoblotting) were determined in different treatment groups in separate sets of experiments. Bumetanide significantly attenuated infarct volume and decreased ipsilateral hemispheric water content in WT mice compared to vehicle treatment. In α-Syn−/− mice, bumetanide treatment had no effect on infarct volume or ischemia-evoked cerebral edema. Bumetanide-treated WT mice had a significant attenuation of AQP4 protein expression at 48 h post-MCAO compared to vehicle-treated WT mice. These data suggest that bumetanide exerts its neuroprotective and anti-edema effects partly via blockade of the perivascular pool of AQP4 and may have therapeutic potential for ischemic stroke in the clinical setting.Keywords
This publication has 45 references indexed in Scilit:
- Inhibition of Aquaporin-1 and Aquaporin-4 Water Permeability by a Derivative of the Loop Diuretic Bumetanide Acting at an Internal Pore-Occluding Binding SiteMolecular Pharmacology, 2009
- Cerebral Blood Flow and Cerebral Edema in Rats With Diabetic KetoacidosisDiabetes, 2008
- The perivascular pool of aquaporin-4 mediates the effect of osmotherapy in postischemic cerebral edema*Critical Care Medicine, 2008
- Lack of Sex-Linked Differences in Cerebral Edema and Aquaporin-4 Expression after Experimental StrokeJournal of Cerebral Blood Flow & Metabolism, 2008
- Effects of chloride flux modulators in an in vitro model of brain edema formationBrain Research, 2006
- Temporary loss of perivascular aquaporin-4 in neocortex after transient middle cerebral artery occlusion in miceProceedings of the National Academy of Sciences of the United States of America, 2006
- Aquaporin‐4 facilitates reabsorption of excess fluid in vasogenic brain edemaThe FASEB Journal, 2004
- Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia.Stroke, 1994
- Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats.Stroke, 1993
- Toxicologic Evaluation of Bumetanide, A Potent Diuretic AgentThe Journal of Clinical Pharmacology, 1981